title: Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial.
abstract: BACKGROUND
  High risk patients with metastatic non small cell lung cancer (NSCLC) including patients with performance status (PS) 2 or elderly with comorbidities do poorly on combination chemotherapy regimens. We evaluated a sequential treatment with Vinorelbine followed by Gemcitabine to determine its effect on survival and the toxicity in this patient population.
  
  
  METHODS
  Forty-two evaluable patients, median age 75, 21 patients with PS 2 and 21 patients with PS 0 or 1, 37 patients with stage IV and five patients with stage III B NSCLC entered the trial. They received Vinorelbine 30 mg/m2, i.v., on days 1+8 every 3 weeks followed by Gemcitabine 1000 mg/m2, i.v., on days 1+8 every 3 weeks, each for two cycles for stable disease or one cycle after best response. Then stable patients continued until progressive disease on Vinorelbine or Gemcitabine according to the patient's preference.
  
  
  RESULTS
  A total of 126 cycles of Vinorelbine were administered to 42 patients, median of three cycles per patient and 74 cycles of Gemcitabine, median of 1.0 cycle per patient. Sixteen patients (38%) achieved PR, 11 patients on Vinorelbine, 5 patients on Gemcitabine; 12 patients (26%) had stable disease, 7 patients on Vinorelbine, 5 patients on Gemcitabine. Of 24 patients with progressive disease on Vinorelbine, 3 patients (12.5%) responded to Gemcitabine. Median time-to-first progression was 3.5 months, median survival was 8 months, 1-year survival was 12 patients (28.5%). No grade 3 or 4 toxicities were reported.
  
  
  CONCLUSIONS
  This sequential treatment offers excellent palliative treatment with minimal toxicity for high-risk patients with metastatic NSCLC.
authors.affiliation: Royal Victoria Hospital, McGill University, 687 Pine Avenue W, Montreal, Que., Canada H3A 1A1. vera.hirsh@muhc.mcgill.ca
authors.forename: Vera
authors.initials: V
authors.lastname: Hirsh
authors.forename: Jean
authors.initials: J
authors.lastname: Latreille
authors.forename: Harvey
authors.initials: H
authors.lastname: Kreisman
authors.forename: Pierre
authors.initials: P
authors.lastname: Desjardins
authors.forename: Linda
authors.initials: L
authors.lastname: Ofiara
authors.forename: Renaud
authors.initials: R
authors.lastname: Whittom
authors.forename: Susan
authors.initials: S
authors.lastname: Fox
authors.forename: Mark David
authors.initials: MD
authors.lastname: Palayew
authors.forename: Javier
authors.initials: J
authors.lastname: Pintos
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000532:radiotherapy*; D015897:Comorbidity; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D016330:Frail Elderly; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine